News

Exelixis suspended new patient enrollment in the ongoing XL999 clinical trials in November 2006, after cardiovascular events were observed. The FDA subsequently placed the clinical program on partial

Ambien, also known as zolpidem tartrate, will be available in 5mg and 10 mg doses from: Mylan Pharmaceuticals, Teva Pharmaceuticals, Roxane Laboratories, Watson Laboratories, Ranbaxy Laboratories, Dr Reddy's

Under the terms of the agreement, GlaxoSmithKline will pay an up-front fee to Astex in return for a license under Astex’s portfolio of granted and pending cytochrome P450

The company expects to launch the new 10mg strength capsule in 2007. Kadian is Alpharma’s branded extended release morphine sulfate product and is currently marketed in 20mg, 30mg,

Actavis now becomes one of the leading companies in the US market in the development of controlled release products (CR), with over 50 CR products in the pipeline

Arrayit said that Arrayit Diagnostics Inc. will spearhead an intensive marketing campaign in an effort to establish Arrayit in the diagnostics sector.

Xcytrin has been developed to treat non-small cell lung cancer (NSCLC) patients with brain metastases. In December 2006, Pharmacyclics sought marketing approval for Xcytrin in combination with radiation

Two separate phase II trials found that in treatment naive, non-dialysis patients Hematide could correct anemia when administered monthly at an appropriate dose. Hematide is a novel synthetic,

The data shows that CEA-BiTE molecules can prevent subcutaneous tumor growth and formation of lung metastases, which triggers an undisclosed payment from MedImmune to Micromet. Micromet holds exclusive